X4 Pharmaceuticals gets FDA agreement to cut 4WARD trial size to 126 patients
The FDA agreed the smaller sample preserves statistical power for the Phase 3 chronic neutropenia trial, with enrollment completion targeted for year-end 2026 and topline data expected in the first half of 2028.
SEC filing